Get the Stockscreener App
469.34
1.84%
-8.79
Vertex Pharmaceuticals Inc stock is traded at $469.34, with a volume of 1.10M.
It is down -1.84% in the last 24 hours and down -4.50% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$478.13
Open:
$481.79
24h Volume:
1.10M
Relative Volume:
0.76
Market Cap:
$119.23B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
30.61
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
+2.77%
1M Performance:
-4.50%
6M Performance:
+18.96%
1Y Performance:
-6.68%
1-Day Range:
$469.08
$486.66
1-Week Range:
$450.78
$507.92
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Prosight Management LP Boosts Vertex Pharmaceuticals Stake - National Today
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Vertex Pharmaceuticals (VRTX)'s IgA Nephropathy Win Means For Its Next Major Franchise Potential - simplywall.st
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Quadrature Capital Ltd Boosts Vertex Pharmaceuticals Stake - National Today
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Merges Strong Fundamentals with Bullish Technical Setup - ChartMill
2 Factors to Consider Investing in VRTX and 1 Reason to Remain Careful - Bitget
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals (VRTX) Pricing In Too Much Optimism After Recent Share Gains? - simplywall.st
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Pharmaceuticals (VRTX) Sees Target Price Raised by Truist Securities | VRTX Stock News - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Acquires 14,706 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CreativeOne Wealth LLC Trims Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma (NASDAQ:VRTX) Market Focus Builds Across Nasdaq Index - Kalkine Media
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo! Finance Canada
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance
Vertex Pharmaceuticals Shares Sold by Schroder Investment Management - National Today
Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Schroder Investment Management Group - MarketBeat
Van ECK Associates Corp Has $58.38 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex preps FDA filing for IgAN drug after phase 3 readout - pharmaphorum
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Scotiabank Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Richard Bernstein Advisors LLC Sells 4,059 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
DE Burlo Group Inc. Sells 43,740 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise - simplywall.st
Blair William & Co. IL Reduces Vertex Pharmaceuticals Stake - National Today
Bank of Montreal Boosts Vertex Pharmaceuticals Holdings by 15.5% - National Today
Vertex Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating - Investor's Business Daily
Bank of Montreal Can Has $164.28 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Narrow-Moat Vertex's Positive Data for Povetacicept Support Diversification Beyond Core CF Franchise - Morningstar
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today - Yahoo Finance
Vertex Pops On 'Remarkable' Results For Chronic Kidney Disease Drug - Investor's Business Daily
Vertex Pharmaceuticals Stock Jumps with Positive Drug Pipeline News - timothysykes.com
Vertex Pharmaceuticals Hits Milestone with Povetacicept Data, Shares Surge - StocksToTrade
These Stocks Are Today’s Movers: BioNTech, NIO, Centene, Vertex, Paramount, Rivian, Occidental, and More - Barron's
Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. - Barron's
Vertex Pharmaceuticals (VRTX) Receives Rating Update and Price T - GuruFocus
Key facts: Vertex Pharmaceuticals reports positive trial results; firms raise price targets - TradingView
Here’s Why Vertex Pharmaceuticals Stock (VRTX) Is Up 10% Today - TipRanks
Vertex Pharma to Seek Speedy FDA Approval for Kidney Disease Drug From $4.9B Acquisition - MedCity News
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send? - TradingKey
Vertex Pharma Stock Rises on IgA Nephropathy Drug Trial Success | 2026News and Statistics - IndexBox
Vertex to seek approval of IgAN drug after Phase III success - Clinical Trials Arena
Vertex Pharmaceuticals Soars on Promising Phase 3 Trial Results for Povetacicept - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $596.00 Price Target at Morgan Stanley - MarketBeat
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study - Finviz
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):